Clinical trial · Interventional
Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer
Phase IIa Study of Metastatic Breast Cancer
NCT00976365CI-TRIAL-00004981completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to obtain evidence from test article with efficacy in Metastatic Breast Cancer patients. The average of all changes from baseline to post-treatment evaluations in global health/quality of life (QoL) subscale assessed by self-administered European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| THL-P | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- THL-P
- description
- Solution for study only.
- interventionNames
- Dietary Supplement: THL-P
- type
- PLACEBO_COMPARATOR
- label
- Sugar pill
- description
- THL-p
- interventionNames
- Dietary Supplement: THL-P
Primary outcomes (1)
- measure
- QOL
- timeFrame
- 6 months measure
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed breast cancer with clinical evidence. * Life expectancy of at least 4 weeks. Exclusion Criteria: * Any Uncontrolled infection. * Lupus erythematosus. * Malignant tumor.
References
Publications (0)
Data not yet available
No reference posted for this study.